These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7934710)

  • 21. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of noninvasive central blood pressure monitoring in the diagnosis of hypertension.
    Cheng HM; Pearson A; Sung SH; Yu WC; Chen CH; Karnon J
    Am J Hypertens; 2015 May; 28(5):604-14. PubMed ID: 25430695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A health-economic comparison of diet and drug treatment in obese men with mild hypertension.
    Johannesson M; Fagerberg B
    J Hypertens; 1992 Sep; 10(9):1063-70. PubMed ID: 1328366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is cost-effectiveness analysis?
    Evans DB
    Med J Aust; 1990 Aug; 153(S1):S7-9. PubMed ID: 2116585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip.
    Chang RW; Pellisier JM; Hazen GB
    JAMA; 1996 Mar; 275(11):858-65. PubMed ID: 8596224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selection of end points in economic evaluations of coronary-heart-disease interventions.
    Drummond MF; Heyse J; Cook J; McGuire A
    Med Decis Making; 1993; 13(3):184-90. PubMed ID: 8412546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
    Panchmatia HR; Clements KM; Hulbert E; Eriksson M; Wittrup-Jensen K; Nilsson J; Weinstein MC
    Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension.
    Edelson JT; Weinstein MC; Tosteson AN; Williams L; Lee TH; Goldman L
    JAMA; 1990 Jan; 263(3):407-13. PubMed ID: 2136759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial.
    Zethraeus N; Borgström F; Jönsson B; Kanis J
    Int J Technol Assess Health Care; 2005; 21(4):433-41. PubMed ID: 16262965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
    Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
    Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K; Persson U
    J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
    Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
    Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):29-36. PubMed ID: 15703503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK.
    Gladwell D; Henry T; Cook M; Akehurst R
    Appl Health Econ Health Policy; 2014 Dec; 12(6):611-22. PubMed ID: 25086585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis: controlled-release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study.
    Saito I; Fujikawa K; Saruta T;
    Hypertens Res; 2008 Jul; 31(7):1399-405. PubMed ID: 18957811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension--the Nifedipine and Candesartan Combination (NICE-Combi) Study.
    Fujikawa K; Hasebe N; Kikuchi K;
    Hypertens Res; 2005 Jul; 28(7):585-91. PubMed ID: 16335887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of renin-guided treatment of hypertension.
    Smith SM; Campbell JD
    Am J Hypertens; 2013 Nov; 26(11):1303-10. PubMed ID: 24048147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.